12/18
08:03 am
rmd
Rating for RMD
Low
Report
Rating for RMD
12/16
06:18 am
rmd
Rating for RMD
Low
Report
Rating for RMD
12/16
06:18 am
rmd
Rating for RMD
Low
Report
Rating for RMD
12/16
05:19 am
rmd
ResMed downgraded to Neutral from Outperform at Baird
Low
Report
ResMed downgraded to Neutral from Outperform at Baird
12/16
05:19 am
rmd
ResMed downgraded to Neutral from Outperform at Baird
Low
Report
ResMed downgraded to Neutral from Outperform at Baird
12/12
12:03 pm
rmd
ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
ResMed (NYSE:RMD) had its "buy" rating reaffirmed by analysts at UBS Group AG.
11/3
07:31 am
rmd
Rating for RMD
Low
Report
Rating for RMD
11/3
07:31 am
rmd
Rating for RMD
Low
Report
Rating for RMD
10/31
11:07 am
rmd
Rating for RMD
Low
Report
Rating for RMD
10/31
11:07 am
rmd
Rating for RMD
Low
Report
Rating for RMD
10/31
09:09 am
rmd
Rating for RMD
Low
Report
Rating for RMD
10/31
09:09 am
rmd
Rating for RMD
Low
Report
Rating for RMD
10/31
08:02 am
rmd
Rating for RMD
Medium
Report
Rating for RMD
10/31
08:02 am
rmd
Rating for RMD
Medium
Report
Rating for RMD
10/21
08:04 am
rmd
ResMed (NYSE:RMD) had its "overweight" rating reaffirmed by analysts at Morgan Stanley. They now have a $304.00 price target on the stock, up previously from $298.00.
Low
Report
ResMed (NYSE:RMD) had its "overweight" rating reaffirmed by analysts at Morgan Stanley. They now have a $304.00 price target on the stock, up previously from $298.00.
10/21
08:04 am
rmd
ResMed (NYSE:RMD) had its "overweight" rating reaffirmed by analysts at Morgan Stanley. They now have a $304.00 price target on the stock, up previously from $298.00.
Low
Report
ResMed (NYSE:RMD) had its "overweight" rating reaffirmed by analysts at Morgan Stanley. They now have a $304.00 price target on the stock, up previously from $298.00.
10/21
07:52 am
rmd
Rating for RMD
Low
Report
Rating for RMD
10/21
07:52 am
rmd
Rating for RMD
Low
Report
Rating for RMD